Usually a banker wants to know how the loan will be repaid. They want collateral or a viable cash flow that demonstrates credit worthiness. Most bankers, imo, dont care if you have the best invention on earth, their first question is about how are you going to pay this loan back. A government guarantee is equally good, even from NEXIM.
I expect cash is flowing into the company already since they commercially launched the drug early in September. There should be an operations interim statement soon about sales. We need a status report. I am sure there will be a question about that at the meeting in Texas.
Secondly, no CEO wants to go into a shareholder meeting with empty hands. He wants the investors to applaud, not cut him up. I would expect he will have loan news even with a "subject to shareholder approval of increased A/S" by the shareholder meeting in October. Of course, next week would do fine. All imo.